Mike Hennessy Jr. is the Chairman and CEO of 

Mike Hennessy Jr.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

The bio/pharmaceutical industry is navigating one of the most consequential periods of transformation in history. From the regulatory frameworks that govern drug approval to the laboratory benches where tomorrow’s cancer therapies are being born, change is happening at every level of the development and manufacturing continuum. This issue of 

 reflects that breadth, bringing together perspectives from scientists, engineers, regulatory strategists, and industry veterans to chart where the field is headed.

Nowhere is this transformation more visible than in the growing role of digital technology in regulatory oversight. As our cover story explores, global regulators are embedding artificial intelligence and digital tools into facility reviews and product evaluation processes. For manufacturers operating in GMP environments, and for sponsors submitting new drug applications, this shift demands a comparable evolution in how data are generated, managed, and presented. The companion piece on FDA’s digital-by-default oversight model goes further, offering a detailed operational roadmap for aligning chemistry, manufacturing, and controls and quality management systems with the agency’s increasingly data-centric expectations.

On the science side, this issue captures an extraordinary moment in oncology. The emergence of chimeric antigen receptor T-cell therapies, antibody-drug conjugates, messenger RNA-based cancer vaccines, and oncolytic virus platforms represents not merely incremental progress but a fundamental reimagining of how cancer is treated. Targets once considered undruggable are yielding to new modalities.

Behind every therapeutic advance, however, lies the unglamorous but indispensable work of manufacturing. Our peer-reviewed feature on Type III rouge remediation offers a timely example: a practical, cost-effective method for addressing a persistent challenge in stainless-steel water systems and equipment that reduces downtime and operator risk through smarter chemistry rather than disruptive mechanical intervention.

Two additional threads run through this issue: sustainability and analytical innovation. Drug manufacturers are making meaningful strides in reducing environmental impact without compromising quality, while advances in small-volume dissolution testing are ensuring that low-dose and combination drug-device products receive the rigorous performance evaluation they require.

Together, these articles paint a picture of an industry under pressure to move faster, operate smarter, and innovate more broadly than ever before while rising to meet that challenge.

Mike Hennessy Jr is Chairman and CEO of MJH Life Sciences®.

Articles

Digitalization is reshaping biopharma across development, regulatory oversight, and manufacturing. Global authorities are integrating AI and data-driven tools into inspections and product evaluation, raising expectations for how GMP data are captured, governed, and submitted. In oncology, next-generation modalities—including CAR T cells, ADCs, mRNA cancer vaccines, and oncolytic viruses—are expanding therapeutic reach, including against historically “undruggable” targets. Manufacturing execution remains pivotal, with practical chemical approaches to Type III rouge remediation reducing downtime and operator risk. Sustainability initiatives and improved small-volume dissolution testing further strengthen product performance evaluation.

This issue of PharmTech brings together perspectives from scientists, engineers, regulatory strategists, and industry veterans to chart where the field is headed.

Innovation Reshaping Pharma’s Future

The bio/pharmaceutical industry is operating at a remarkable intersection of scientific discovery, regulatory evolution, and manufacturing sophistication. This issue of 

 captures that convergence across its full scope, from the regulatory frameworks reshaping how drugs are approved and monitored, to the emerging therapies redefining what is therapeutically possible, to the operational realities of producing complex medicines safely and sustainably.

Digital transformation continues to set the pace for regulatory affairs. Our cover story examines how regulators are integrating artificial intelligence and advanced digital tools into facility inspections and product reviews, creating new expectations for pharmaceutical companies navigating the approval process and for manufacturers upholding good manufacturing practice standards. The quality theme continues in our manufacturing article, which examines how incorporating sustainability into the early development phase creates greener pharmaceutical manufacturing.

Europe, meanwhile, is charting its own course. This issue spotlights a compelling frontier in immunology: proteasome-targeting therapies, which hold promise for eliminating disease-causing proteins across a wide range of conditions. Combined with the latest European Regulatory Watch, these features reflect the increasingly global and scientifically ambitious character of drug development today.

On the development front, the oncology pipeline remains one of the most dynamic in the industry. Chimeric antigen receptor T-cell (CAR-T) and other cell-based immunotherapies, antibody-drug conjugates, messenger RNA cancer vaccines, and oncolytic virus platforms are advancing through the clinic, collectively targeting disease pathways that were, until recently, considered beyond reach. The breadth of these modalities signals a new era of precision oncology.

Translating these advances into reliable, scalable products demands manufacturing excellence. Our peer-reviewed feature addresses a persistent challenge in pharmaceutical water systems (type III magnetite rouge), presenting a smarter remediation approach that cuts downtime, reduces operator risk, and preserves equipment integrity. Ensuring the purity and sterility of those products is equally critical, and our analytics feature explores the evolving landscape of analytical technologies for aseptic processing, from current best practices to emerging innovations on the horizon.

Rounding out the issue, our outsourcing coverage examines how CDMOs are adapting their formulation services to meet the demands of patient-centric therapies and rare disease treatments, a reflection of how deeply personalized medicine is reshaping the contract services landscape.

Across every section, a single theme emerges: an industry building the future with rigor, creativity, and purpose.

Pharma's Digital, Scientific, and Manufacturing Evolution

 has been the voice for practical, real-world strategy. We make complex breakthroughs professionally applicable, and we fundamentally drive advanced development and manufacturing every day.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

We earned our place as the market leader by creating uniquely expert content and engaging media platforms. Through 2025, we developed a bold, new look and content strategy. The design is incredible and we’re excited for you to experience it.

Our content authority comes from alignment with top experts across the field. By staying united with key opinion leaders in pharma, we can deliver impartial and objective insights. Our new media strategy elevates these stars, giving them the spotlight they deserve.

For more than 25 years, the official name has been 

. You do, too. Everyone does. Why? It’s precise. Gets right to the point. It’s picture-perfect for our approach to the industry.

Call us humble. We earned #1, and we focus on excellence. But this industry is defined by competition. So, we’re putting on the gloves as the comprehensive leader in engagement with key decision-makers in pharma and biopharma. Reach, quality, versatility—always.

Mike Hennessy Jr
President and CEO
MJH Life Sciences

Bold vision. Grand scale.

The pharmaceutical sector continues to evolve at a remarkable pace, shaped by scientific breakthroughs, growing operational complexity, and heightened regulatory expectations. This issue highlights the industry’s ongoing effort to balance innovation with control—ensuring that as technologies and therapeutic modalities advance, manufacturing and quality systems advance alongside them.

Our cover story, “How a ‘Plan, Prevent, Prove’ Approach Helps Avoid Facility and Equipment Problems,” captures a core challenge for good manufacturing practice operations today: anticipating failure before it occurs. As facilities become more interconnected and equipment more sophisticated, risk-based planning and disciplined maintenance have become essential.

On the development front, Cynthia A. Challener, PhD, examines the increasingly complex world of highly potent APIs in “Trends and Challenges Impacting Highly Potent API Development.” The rising demand for targeted and potent therapies is driving investment in containment technologies, specialized infrastructure, and new approaches to worker and product safety. These pressures are reshaping how companies think about HPAPI innovation and scale-up.

Challener also explores the manufacturing implications of these shifts in “Leap Forward in Automation Anticipated for Small-Molecule Drug Product Manufacturing.” With formulation complexity growing and the need for efficiency intensifying, small-molecule manufacturers are turning to automation to reduce manual operations, enhance consistency, and streamline production timelines.

In “How Therapeutic and Analytical Advancements Help Drug Substance Testing Evolve,” Patrick Lavery highlights how advances in both therapies and technologies are redefining modern analytical strategies. He explores trends in sustainability, stability testing, and the emerging role of artificial intelligence in quality assessment. Rounding out the issue, the Ask the Expert feature offers an overview of batch recovery fundamentals, an essential reminder that strong foundational practices remain critical, even as the industry embraces new tools and capabilities. Together, these articles reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

®
Vol. 49, No. 9
November/December 2025
Page: 8

When referring to this article, please cite it as Hennessy, M. How Innovation and Risk Management Are Reshaping Modern Drug Manufacturing. 

The pharmaceutical industry is rapidly evolving, driven by scientific advancements, operational complexities, and regulatory demands. Balancing innovation with control is crucial as technologies and therapeutic modalities progress. Key challenges include anticipating equipment failures and adapting to the complexities of highly potent APIs. Automation is becoming essential in small-molecule drug manufacturing to enhance efficiency and consistency. Advances in therapies and technologies are reshaping analytical strategies, with sustainability and AI playing significant roles. Despite these innovations, foundational practices like batch recovery remain vital for safe and reliable pharmaceutical production.

The articles in this issue reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

How Innovation and Risk Management Are Reshaping Modern Drug Manufacturing

Each new chapter in pharmaceutical innovation underscores a simple truth: the path from molecule to medicine is never linear. Scientific discovery, technological evolution, and market demands constantly reshape the landscape, requiring both agility and vision from every stakeholder. This issue of 

 captures the state of that journey, one that is as much about mastering fundamentals as it is about embracing new tools and approaches. Our cover story, “The Evolving Science Behind Formulation Development,” explores strategies across the drug product lifecycle. Vaibhav Sihorkar, PhD, of Aragen Life Sciences, offers insights into problem solving, the role of digital tools, and how geopolitical change is influencing formulation decisions from a CRDMO’s perspective. The complex area of drug formulation is further explored in “Personalized and Patient-Centric Administration of Oral Medicines,” which highlights how individualized therapies are moving forward despite the challenges of scalability and regulation.

On the business front, Ana Ali of RCK Partners provides a perspective on R&D tax relief in the United Kingdom, and Cheryl Barton, PharmaVision, hightlights the companies entering the metabolic dysfunction-associated steatohepatitis arena.

Ensuring product quality remains at the forefront. This issue’s European Regulatory Watch details Europe’s strategy to become an attractive location for life sciences innovation, and the Ask the Expert feature outlines best practices for implementing contamination control strategies.

On the manufacturing front, “Keys to Navigating the Complex Drug Supply Chain” shows how digital tools help manufacturers adapt to ongoing global volatility.

As a whole, this issue reveals an industry strengthening its foundation while embracing innovation. Success now demands not just advanced tools and processes, but collaboration, resilience, and a focus on improving outcomes for patients worldwide.

Pharmaceutical innovation is a complex journey shaped by scientific, technological, and market dynamics. Stakeholders must balance mastering fundamentals with adopting new tools and approaches. Insights from Aragen Life Sciences highlight the impact of digital tools and geopolitical changes on formulation decisions. Personalized therapies face scalability and regulatory challenges. R&D tax relief and new entrants in the metabolic dysfunction-associated steatohepatitis field are discussed. Europe's strategy for life sciences innovation and best practices for contamination control are outlined. Digital tools aid manufacturers in navigating the volatile drug supply chain.

Success depends on collaboration, resilience, and a focus on improving outcomes for patients worldwide.

Resilience and Precision in Pharma Development

The pharmaceutical industry is in a period of rapid transformation, driven by scientific innovation, regulatory expectations, and the increasing complexity of therapies. This issue highlights the most pressing trends shaping the sector and the strategies that organizations are adopting to stay competitive.

In our cover story, Susan Haigney explores innovative approaches to bioanalysis, in which automation and novel methodologies are expanding capabilities for faster and more reliable results. As the complexity of drug modalities increases, bioanalytical innovation is no longer optional; it is essential for ensuring product safety, regulatory compliance, and development speed.

Equally critical is formulation development. Cynthia Challener examines how artificial intelligence (AI) and machine learning are being applied to predictive modeling for small molecules, where drug candidates present formidable challenges in molecular complexity and delivery.

Advances in digitalization and automation of aseptic processing are helping organizations address the growing diversity of injectable drug products. Streamlined, technology-enabled approaches are reducing human intervention, improving sterility assurance, and enhancing scalability.

This issue also delves into mechanistic modeling of renal clearance, with Akanksha Prasad providing insights into optimizing dosing strategies for elderly patients. As patient populations age, this type of research is vital to balancing efficacy with safety in clinical care.

Data integration and digital transformation remain central to the industry’s progress. Jennifer Markarian highlights how better use of process data, enhanced by AI and advanced analytics, is enabling smarter process control and more connected manufacturing systems.

Patrick Lavery examines FDA’s push for greater quality, integrity, and uniformity, particularly in the context of advanced manufacturing and batch control. Our Ask the Expert section takes a look at the importance of real-world evidence used in pharmacovigilance.

As these articles show, the future of pharma lies in a careful balance: adopting cutting-edge technologies while upholding rigorous standards of quality and safety. The organizations that succeed will be those that embrace innovation while keeping patients at the center of every decision.

When referring to this article, please cite it as Hennessy, M. From Discovery to Delivery: Evolving Practices in Pharma. 

The pharmaceutical industry is undergoing rapid transformation due to scientific innovation, regulatory demands, and complex therapies. Key trends include bioanalytical advancements, AI in formulation development, and digitalization in aseptic processing. These innovations are crucial for ensuring safety, compliance, and efficiency. Mechanistic modeling is optimizing dosing for aging populations, while data integration enhances process control. The FDA emphasizes quality and uniformity in advanced manufacturing. Success in the industry hinges on adopting new technologies while maintaining high standards of quality and patient-centered care.

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.